Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial

E. Elez, S. Siena, A. Sartore-Bianchi, J. Ros, F. Ciardello, E. Martinelli, N. Steeghs, S. Huijberts, A. Cervantes, S. Roselló, S. Tejpar, B. Wilmsen, R. Salazar, C. Santos, G. de Schaetzen, S. Muñoz, R. Bernards, V. Moreno, E. García-Galera, R. Alemany, A. Gros, A. Bardelli, S. Arena, A. Piris, E. Chavarría, R. Dienstmann, J. Tabernero

Open source

DOI: 10.1016/j.esmoop.2025.105892
Published: 2025-12
Container: ESMO Open
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2025.105892,
  title = {Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial},
  author = {E. Elez and S. Siena and A. Sartore-Bianchi and J. Ros and F. Ciardello and E. Martinelli and N. Steeghs and S. Huijberts and A. Cervantes and S. Roselló and S. Tejpar and B. Wilmsen and R. Salazar and C. Santos and G. de Schaetzen and S. Muñoz and R. Bernards and V. Moreno and E. García-Galera and R. Alemany and A. Gros and A. Bardelli and S. Arena and A. Piris and E. Chavarría and R. Dienstmann and J. Tabernero},
  year = {2025},
  journal = {ESMO Open},
  doi = {10.1016/j.esmoop.2025.105892},
  url = {https://doi.org/10.1016/j.esmoop.2025.105892}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial
AU  - E. Elez
AU  - S. Siena
AU  - A. Sartore-Bianchi
AU  - J. Ros
AU  - F. Ciardello
AU  - E. Martinelli
AU  - N. Steeghs
AU  - S. Huijberts
AU  - A. Cervantes
AU  - S. Roselló
AU  - S. Tejpar
AU  - B. Wilmsen
AU  - R. Salazar
AU  - C. Santos
AU  - G. de Schaetzen
AU  - S. Muñoz
AU  - R. Bernards
AU  - V. Moreno
AU  - E. García-Galera
AU  - R. Alemany
AU  - A. Gros
AU  - A. Bardelli
AU  - S. Arena
AU  - A. Piris
AU  - E. Chavarría
AU  - R. Dienstmann
AU  - J. Tabernero
PY  - 2025
JO  - ESMO Open
DO  - 10.1016/j.esmoop.2025.105892
UR  - https://doi.org/10.1016/j.esmoop.2025.105892
ER  -

APA

Elez, E., Siena, S., Sartore-Bianchi, A., Ros, J., Ciardello, F., Martinelli, E., Steeghs, N., Huijberts, S., Cervantes, A., Roselló, S., Tejpar, S., Wilmsen, B., Salazar, R., Santos, C., Schaetzen, G. D., Muñoz, S., Bernards, R., Moreno, V., García-Galera, E., Alemany, R., Gros, A., Bardelli, A., Arena, S., Piris, A., Chavarría, E., Dienstmann, R., & Tabernero, J. (2025). Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial. ESMO Open. https://doi.org/10.1016/j.esmoop.2025.105892

Source records

crossref · retrieved 2026-09-25T11:49:41.600Z